Real-world Dapagliflozin Treatment in Patients With Heart Failure in Portugal (EVOLUTION-HF) - EVOLUTION-HF

Study identifier:D1699R00036

ClinicalTrials.gov identifier:NCT05465213

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

Early treatment of heart failure: a non-interventional observational study of patients with heart failure and initiated on dapagliflozin in Portugal

Medical condition

heart failure

Phase

Phase 4

Healthy volunteers

No

Study drug

-

Sex

All

Actual enrollment

355

Study type

Observational

Age

n/a - n/a

Date

Study Start Date: 28 Nov 2022
Estimated Primary Completion Date: 31 Dec 2023
Estimated Study Completion Date: 31 Dec 2023

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 May 2023 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria